Connect with us

News

Startup Funding At Abu Dhabi’s Hub71 Reaches $871M

According to the deputy chief executive, companies within the organization have generated over $680 million and created hundreds of direct jobs.

Published

on

startup funding at abu dhabi's hub71 reaches $871m

Hub71, Abu Dhabi’s global technology ecosystem, has raised more than $871 million in funding for startups and created 800 jobs since its creation in 2019, until September of this year, according to the latest figures. The organization now boasts around 200 members, and is contributing significantly to the region’s economy, intending to grow 20 startups into companies worth over $1 billion.

“There was a resurgence in investor interest at Hub71 after the effects of the COVID-19 pandemic wore off. The momentum has been helping the ecosystem and partner network to support Abu Dhabi, which is increasingly positioning itself as one of the global epicenters of technology. There was a huge thirst to get out there to engage with partners to identify opportunities, and that momentum continues to this day,” says Ahmad Alwan, Hub71 deputy chief executive.

Abu Dhabi has invested heavily in initiatives that contribute to technology and innovation, and Hub71, in particular, is helping the country to promote entrepreneurship as the UAE government aims to become “the entrepreneurial nation by 2031“.

Also Read: Hybrid Cloud As A Driver Of Digital Transformation In Saudi Arabia

Globally, the money generated by startups is close to $3 trillion — a staggering figure that almost matches the output of the G7 economy — Mr. Alwan said Hub71 had “several initiatives in the pipeline that are being planned with its partners”, which are rumored to include wealthy venture capital companies and funds, with the hope that one day, a local Abu Dhabi startup will become a global technology corporation.

Hub71 is open to the idea of expanding its “bilateral relationships” with partners in different regions, though right now, the ecosystem is focused on helping to develop its member companies by taking advantage of its existing partnerships.

In August, Hub71 welcomed 16 new startups to its platform and recently joined forces with Siemens Energy to support Abu Dhabi’s fight against climate change.

Advertisement

📢 Get Exclusive Monthly Articles, Updates & Tech Tips Right In Your Inbox!

JOIN 17K+ SUBSCRIBERS

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

Orchid Plans To Find Out What’s Wrong With You Before You’re Born

According to CEO Noor Siddiqui, the company isn’t on a mission to make designer babies, but aims to beat genetic odds and relieve suffering.

Published

on

startup orchid plans to find out what's wrong with you before you're born
Orchid

Each day, around 400,000 babies are welcomed into the world. However, among those, a growing number will experience some kind of birth defect or inherited disease.

Noor Siddiqui, CEO of Orchid, hopes to “mitigate” unpleasant genetic surprises using genome sequencing technology to reveal a wealth of genetic information on which newborns will grow into healthy adults.

Until 2019, IVF specialists had access to under 1% of the human genome. The tests, called PGT-A and PGT-M, scanned a mere 1,000 data points in a genome comprising around 3 billion bases, offering a very limited dataset compared to the technology used by Orchid.

“Our chromosomes are like chapters in a book that make up the table of contents.” Explained Siddiqui. “[PGT-A and PGT-M tests] only examine the table of contents, whereas what Orchid is doing is like a spellcheck on the entire book.” Orchid’s genome sampling technology assesses “100 times the data, covering many more conditions.” In essence, an Orchid report covers three categories of common genetic issues: monogenic disorders, polygenic conditions, and de-novo mutations.

Also Read: Advancing MENA Health Through AI Vascular Age Analysis

Orchid’s technology raises many questions. Aside from the obvious ethical concerns, data privacy is the most obvious potential issue with the tests. Noor Siddiqui is keen to alleviate any concerns: “No data at Orchid is ever sold to any third parties. Parents are in complete control of their data. If they want to delete the data, we’re happy to delete it off of our servers. If they want to export the data, they can export the data. And if they want us to re-analyze the data, we can re-analyze the data”.

Compared to a lifetime of medical bills, gene therapy, and suffering, Orchid’s genome screening report has the potential to change the future lives of thousands of newborns worldwide.

Continue Reading

#Trending